Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process.
Cancelas JA, Dumont LJ, Rugg N, Szczepiorkowski ZM, Herschel L, Siegel A, Pratt PG, Worsham DN, Erickson A, Propst M, North A, Sherman CD, Mufti NA, Reed WF, Corash L.
Cancelas JA, et al.
Transfusion. 2011 Nov;51(11):2367-76. doi: 10.1111/j.1537-2995.2011.03163.x. Epub 2011 May 13.
Transfusion. 2011.
PMID: 21569044
Clinical Trial.